Press release
The antibody drug conjugates market is estimated to be worth more than 15 billion in 2030, predicts Roots Analysis
Roots Analysis is pleased to announce the publication of its recent study, titled, “Antibody Drug Conjugates Market (5th Edition), 2019-2030.”
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these therapeutics over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
A detailed assessment of the current market landscape of ADCs.
Elaborate profiles of the clinical stage companies (shortlisted based on phase of development of the lead drug) and their respective product portfolios.
An analysis of the most commonly targeted therapeutic indications and details of ADC candidates being developed against them, highlighting key epidemiological facts about the diseases and currently available treatment options, other than ADCs.
A list of key opinion leaders (KOLs) within this domain.
An insightful competitiveness analysis of biological targets.
An analysis of the partnerships that have been established in the recent past.
An analysis of the investments made.
A study of the various grants that have been awarded to research institutes engaged in projects related to ADCs, between 2011 and 2019 (till April).
An elaborate discussion on the various strategies that can be adopted by the drug developers across key commercialization stages, namely prior to product launch, during / post launch.
An analysis of the key promotional strategies that have been adopted by the developers of marketed products.
An assessment of the various therapeutics that are being evaluated in combination with ADCs.
A review of the evolution of ADC conjugation technologies.
An overview of the studies conducted to better analyze non-clinical data and support first-in-human (FIH) dose selection in ADCs.
An elaborate discussion on various factors that form the basis for the pricing of ADC products.
A case study on manufacturing of ADCs, highlighting the key challenges, and a list of contract service providers that are involved in this domain.
A case study on companies offering companion diagnostics.
A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)
Type of payload
MMAE
DM4
Camptothecin
AM1
MMAF
Type of linker
VC
Sulfo-SPDB
SMCC
VA
Hydrazone linker
Others
Target Indications
Breast Cancer
Lymphoma
Leukemia
Urothelial cancer
Lung cancer
Ovaria cancer
Others
Target Antigen
CD30
HER2
CD22
CD33
Others
Small Molecule
Technology Providers
Seattle Genetics
ImmunoGen
StemCentRx
Immunomedics
Others
Key Geographies
North America
Europe
Asia Pacific
Transcripts of interviews held with the following senior level representatives of stakeholder companies:
Alan Burnett (Professor, School of Medicine, Cardiff University)
Aldo Braca (President and Chief Executive Officer) and Giorgio Salciarini (Technical Business Development Senior Manager, BSP Pharmaceuticals)
Anthony DeBoer (Director, Business Development, Synaffix)
Christian Bailly (Director of CDMO, Pierre Fabre)
Christian Rohlff, (Chief Executive Officer and Founder, Oxford BioTherapeutics)
Denis Angioletti (Chief Commercial Officer, Cerbios-Pharma)
John Burt (Chief Executive Officer, Abzena)
Jennifer L. Mitcham (Director, SMARTag ADCs and Bioconjugates) and Stacy McDonald (Group Product Manager, Catalent Pharma Solutions)
Laurent Ducry (Head of Bioconjugates Commercial Development, Lonza)
Mark Wright (Site Head, Piramal Healthcare)
Sasha Koniev (Chief Executive Officer & Co-Founder, Syndivia)
Tatsuya Okuzumi (Associate General Manager, Ajinomoto Bio-Pharma Services)
Toshimitsu Uenaka (Executive Director) and Takashi Owa (Chief Innovation Officer, Eisai)
Wouter Verhoeven (Chief Business Officer, NBE-Therapeutics)
Key companies covered in the report
Bristol Myers Squibb
AbbVie
Astellas Pharma
AstraZeneca
Daiichi Sankyo
Pfizer
Roche / Genentech
Synthon
Bayer HealthCare
Biotest Pharmaceuticals
For more information please click on the following link:
https://www.rootsanalysis.com/reports/view_document/antibody-drug-conjugates-market-5th-edition-2019-2030/270.html
Other Offerings
1. ADC Contract Manufacturing Market (3rd Edition), 2018-2030
2. Gene Therapy Market (3rd Edition), 2019 - 2030
3. Global T-Cell (CAR-T, TCR, and TIL) Therapy Market (4th Edition), 2019 – 2030
Contact:
Gaurav Chaudhary
gaurav.chaudhary@rootsanalysis.com
Roots Analysis
A430, 4th Floor,
Bestech Business Towers, Sector 66, Mohali, India
sales@rootsanalysis.com
+1 (415) 800 3415
+44 (122) 391 1091
Web: https://www.rootsanalysis.com/
LinkedIn: https://in.linkedin.com/company/roots-analysis
Twitter: https://twitter.com/RootsAnalysis
Roots Analysis is one of the fastest growing market research companies, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like help with your growing business needs, get in touch at info@rootsanalysis.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release The antibody drug conjugates market is estimated to be worth more than 15 billion in 2030, predicts Roots Analysis here
News-ID: 2204240 • Views: …
More Releases from Roots Analysis
Autoinjectors Market CAGR to Exceed 6.2% by 2035, Due To The Growing Demand For …
According to our latest market report "Global Autoinjectors Market" by Usability, Route of Administration, Type of Molecule Delivered, Type of Actuation Mechanism, Volume of Container, End User, Target Indication and Key Geographical Regions: Industry Trends and Global Forecasts, till 2035", the global autoinjectors market size is projected to reach around USD 176 billion by 2035 from USD 96.2 billion, growing at a CAGR of 6.2% in the forecast period 2024-2035.…
Medical Aesthetics Market CAGR To Be Around 9.4% by 2035, Due To The Growing Dem …
According to our latest market report "Medical Aesthetics Market, Till 2035 by Type of Products and / or Devices Offered, Type of Procedure, End-user, Gender, Distribution Channel and Key Geographical Regions: Industry Trends and Global Forecasts", the global medical aesthetics market size is projected to reach USD 102 billion by 2035 from USD 35 billion in 2023, growing at a CAGR of 9.4% in the forecast period 2023-2035.
The increasing…
In Vitro Diagnostics Market Size to Hit USD 190 billion by 2035 | Exclusive Repo …
The In Vitro Diagnostics Market size was valued at USD 108 billion in 2024 and likely to hit over USD 190 billion by 2035, growing at a CAGR of 5.2% during the forecast period 2024 to 2035
In vitro diagnostics (IVD) are the tests conducted on samples retrieved from human body, such as blood, saliva or tissue in order to detect diseases or conditions. Such tests help diagnose, monitor, and manage…
Skincare Market Revenue to Cross USD 405 billion by 2035 | Roots Analysis
According to our latest market report "Skincare Market by Type of Product by Application, Type of Product by Body Part, Distribution Channel, Type of Offline Distribution Channel, Type of Packaging, Product Category, Gender, Type of Ingredient, and Geography: Industry Trends and Global Forecasts, till 2035", the global skincare market size is projected to reach USD 407 billion by 2035 from USD 185 billion in 2024, growing at a CAGR of…
More Releases for ADC
Latest Azodicarbonamide (ADC) Market 2022 | Detailed Report
The market report delivers an all-inclusive analysis of the market structure along with a forecast of the various segments and sub-segments of the Azodicarbonamide (ADC) industry. This wide-ranging market research report acts as a backbone for the success of business in any niche. The Azodicarbonamide (ADC) market survey report has been prepared by conducting market research in a systematic manner. Moreover, the Azodicarbonamide (ADC) report includes a professional in-depth study…
Global ADC Blowing Agents Market Analysis by 2020-2025
Global Info Research offers a latest published report on ADC Blowing Agents Analysis and Forecast 2019-2025 delivering key insights and providing a competitive advantage to clients through a detailed report. This report focuses on the key global ADC Blowing Agents Concentrate players, to define, describe and analyze the value, market share, market competition landscape, SWOT analysis and development plans in next few years.
Click to view the full report TOC, figure…
ADC Blowing Agents Market Demand by 2025: QY Research
Global ADC Blowing Agents market report is first of its kind research report that covers the overview, summary, market dynamics, competitive analysis, and leading player’s various strategies to sustain in the global market. This report covers five top regions of the globe and countries within, which shows the status of regional development, consisting of market value, volume, size, and price data. Apart from this, the report also covers detail information about…
Global Data Converters Market Report 2017 (Analog to Digital Converter, Current …
The research report titled Global Data Converters Sales Market Report 2017 market size and forecast and overview on current market trends.
This report studies sales (consumption) of Global Data Converters Market 2017, especially in United States, China, Europe and Japan, focuses on top players in these regions/countries, with sales, price, revenue and market share for each player in these regions, covering
National Semiconductor
Nippon Precision Circuits Inc
Micro Analog systems
Microchip Technology.
TelCom Semiconductor, Inc
Vishay Siliconix
Texas…
SMi’s inaugural ADC Summit, 23rd & 24th May 2012, London
Antibody Drug Conjugates are used to fight cancerous cells and are made up of the antibody that will target a specific tumour0-associated antigen a drug often described as payload and the linker. This results in a drug being delivered selectively to the appropriate malignant cell due to the antibody targeting and specific antigen
With less than a month away, join SMi at their inaugural ADC Summit conference that will provide a…
ADC African Development Corporation GmbH & Co. KGaA: ADC exits shareholding in E …
ADC African Development Corporation (ADC), ISIN DE000A1E8NW9, a fast growing financial services group focusing on the frontier markets of sub-Saharan Africa, has successfully negotiated an exit for its 11.5% shareholding in Ecobank Zimbabwe for USD 5.2 million equaling approx. EUR 4.0 million. As of 30 September 2011, ADC had valued its shareholding in Ecobank Zimbabwe at EUR 1.25 million, so this transaction results in a realized profit of EUR 2.75…
